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Background: Mortality after pneumonia in immunocompromised patients is higher than for immunocompetent
patients. The use of non-invasive mechanical ventilation for patients with severe pneumonia may provide beneficial
outcomes while circumventing potential complications associated with invasive mechanical ventilation. The aim of
our study was to determine if the use of non-invasive mechanical ventilation in elderly immunocompromised
patients with pneumonia is associated with higher all-cause mortality.
Methods: In this retrospective cohort study, data were obtained from the Department of Veterans Affairs
administrative databases. We included veterans age ≥65 years who were immunocompromised and hospitalized
due to pneumonia. Multilevel logistic regression analysis was used to determine the relationship between the use
of invasive versus non-invasive mechanical ventilation and 30-day and 90-day mortality.
Results: Of 1,946 patients in our cohort, 717 received non-invasive mechanical ventilation and 1,229 received
invasive mechanical ventilation. There was no significant association between all-cause 30-day mortality and
non-invasive versus invasive mechanical ventilation in our adjusted model (odds ratio (OR) 0.85, 95% confidence
interval (CI) 0.66-1.10). However, those patients who received non-invasive mechanical ventilation had decreased
90-day mortality (OR 0.66, 95% CI 0.52-0.84). Additionally, receipt of guideline-concordant antibiotics in our
immunocompromised cohort was significantly associated with decreased odds of 30-day mortality (OR 0.31,
95% CI 0.24-0.39) and 90-day mortality (OR 0.41, 95% CI 0.31-0.53).
Conclusions: Our findings suggest that physicians should consider the use of non-invasive mechanical ventilation,
when appropriate, for elderly immunocompromised patients hospitalized with pneumonia.
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Pneumonia is the most common cause of death for all in-
fectious diseases [1], and together, pneumonia and influ-
enza comprise the eighth leading cause of death in the
United States [2]. Much has been done to improve
outcomes for patients with pneumonia, including the estab-
lishment of national practice guidelines for community-* Correspondence: eric.mortensen@utsouthwestern.edu
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stated.acquired pneumonia [3]. However, less information is avail-
able for immunocompromised patients. The immunocom-
promised are at an increased risk of developing pneumonia
[4] and have a higher pneumonia mortality rate [5]. Further,
the Infectious Diseases Society of America and the Ameri-
can Thoracic Society guidelines do not specifically address
pneumonia amongst the immunocompromised [3].
Often, patients with severe pneumonia require endo-
tracheal intubation and mechanical ventilation, which is as-
sociated with complications such as arrhythmia, infection,
and other complications [6]. These complications may be
more detrimental in immunocompromised patients. Non-l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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livering mechanical ventilation without employing the need
for intubation [7]. Previous studies have evaluated the use
of NIV in immunocompromised pneumonia patients
[8-11]. Beneficial effects regarding the use of NIV have
been demonstrated by several studies [9,12,13], while other
studies have shown no benefits with its use [11,14].
The purpose of our study was to explore the associ-
ation between all-cause mortality and NIV versus inva-
sive mechanical ventilation for elderly patients (ages 65
and older) who were immunocompromised and admit-
ted to the hospital with pneumonia. Our hypothesis is
that all-cause mortality will be similar in patients receiv-
ing NIV and invasive mechanical ventilation.
Methods
For this retrospective cohort study, data were obtained
from the Department of Veterans Affairs (VA) Health
Care System administrative databases, which contain
clinical data from over 150 VA hospitals and 850 out-
patient clinics. A prior paper provides the methods in
more detail [15].
Patients were eligible to be included in this study if
they:
a) Were hospitalized between October 1, 2001 and
September 30, 2007.
b) Had a previously validated discharge diagnosis of
pneumonia: either a primary diagnosis of
pneumonia/influenza (ICD-9 codes 480.0-483.99 or
485–487) or a secondary discharge diagnosis of
pneumonia with a primary diagnosis of respiratory
failure (ICD-9 code 518.81) or sepsis (ICD-9 code
038.xx).
c) Were ≥65 years of age on admission.
d) Were immunocompromised: by their receipt of
immunosuppressive medications, oral
corticosteroids, acquired immune deficiency
syndrome (AIDS) (ICD-9 code 42, 43, or 44),
leukemia/multiple myeloma (ICD-9 code 203, 204,
205, 206, 207, or 208), or lymphoma (ICD-9: 200,
201, 202.0, 202.1, 202.2, 202.3, 202.5, 202.6, 202.7,
202.8, 202.9, 203.01, 203.80, 203.81, 238.6, 273.3,
V10.71, V10.72, or V10.79)
e) Had at least one VA outpatient clinic visit in the
year preceding admission.
f ) Received at least one outpatient medication from a
VA pharmacy within 90-days of admission.
g) Received either NIV or invasive mechanical
ventilation during the hospitalization.
Patients were classified as taking an immunosuppres-
sant medication if they received any of the following
drugs within 90 days prior to admission: adalimumab/Humira, azathioprine, bleomycin, cisplatin, cyclophospha-
mide, cyclosporine, doxorubicin, daunorubicin, etanercept/
Enbrel, fludarabine, infliximab/Remicade, methotrexate
sodium, plicamycin/Mithracin, mitomycin, muromonab,
mycophenolate/CellCept, natalizumab/Tysabri, prednisone,
sirolimus, or tacrolimus. Also, patients were classified
as taking oral corticosteroid therapy if they received any
of the following medications within 90 days prior to ad-
mission: cortisone, dexamethasone, hydrocortisone, methyl-
prednisolone, prednisolone, or prednisone.
Invasive vs. non-invasive ventilation
A dichotomized variable indicating NIV (1) versus invasive
mechanical ventilation (0) was created. NIV included both
continuous positive airway pressure and intermittent posi-
tive pressure breathing, and was determined by the pres-
ence of ICD-9 codes 93.90 or 93.91. Invasive mechanical
ventilation (intubation) status was determined by the pres-
ence of ICD-9 code 96.7x. Patients receiving both NIV
and invasive mechanical ventilation during their index
hospitalization were excluded from the analysis.
Outcomes
Outcomes included all-cause 30-day and 90-day mortal-
ity. Mortality status was assessed using the VA Vital
Status file.
Covariates
Explanatory variables included age at admission, gender,
drug counts within 90 days prior to admission (cardio-
vascular, diabetic, pulmonary, and inhaled corticoster-
oid), and number of primary clinical care and emergency
department visits within 90 days prior to the admission.
Indicator variables for smoking cessation status, alcohol
abuse, drug abuse, hospital admission up to 90 days
prior, race and ethnicity, marital status, VA priority
group (a proxy for socioeconomic status), admission to
the intensive care unit (ICU), nursing home residence
prior admission, vasopressor use, and receipt of American
Thoracic Society guideline-concordant antimicrobial
therapy [3] were included, as well as cause/s of im-
munosuppression. VA priority groups are a way for the
VA to focus limited funds to those veterans most in
need. The highest group (priority group 1) must have at
least a 50% service-connected disability. Priority groups
2 through 6 includes veterans with up to 40% service-
connected disability, former prisoners of war, those
awarded certain honors, veterans with lower incomes, and
the catastrophically disabled. The lowest groups (priority
groups 7 and 8) include veterans with relatively higher
incomes who agree to pay copayments [16]. Additionally,
prior ICD-9 codes were used to classify comorbidities
using the previously validated Charlson-Deyo method-
ology (see Table 1) [17].
Table 1 Comparison of cohort by type of ventilatory support
Variables Non-invasive mechanical
ventilation (N = 717)
Invasive mechanical
ventilation (N = 1,229)
p-value
N (%) N (%)
Age at admission, mean (SD) 75.8 (6.2) 75.3 (6.0) 0.07
Men 706 (98.5) 1216 (98.9) 0.36
Smoker 332 (46.3) 492 (40.0) 0.01
Alcohol abuse 30 (4.2) 64 (5.2) 0.31
Prior admission 203 (28.3) 409 (33.3) 0.02
Guideline concordant antibiotics 630 (87.9) 889 (72.3) <0.01
Black 67 (9.3) 147 (12.0) 0.08
White 601 (83.8) 1014 (82.5) 0.46
Hispanic 24 (3.4) 93 (7.6) <0.01
Married 393 (54.8) 633 (51.5) 0.16
VA priority group 0.97
1 137 (19.1) 229 (18.7)
2–6 509 (71.0) 876 (71.3)
7–8 71 (9.9) 123 (10.0)
ICU admission 425 (59.3) 1124 (91.5) <0.01
Myocardial infarction 45 (6.3) 116 (9.4) 0.02
Congestive heart failure 258 (36.0) 387 (31.5) 0.04
Peripheral vascular disease 108 (15.1) 194 (15.8) 0.67
Cerebrovascular disease 93 (13.0) 181 (14.7) 0.28
Dementia 13 (1.8) 34 (2.8) 0.19
Chronic obstructive pulmonary disease 590 (82.3) 821 (66.8) <0.01
Rheumatologic disease 23 (3.2) 61 (5.0) 0.07
Peptic ulcer disease 24 (3.4) 44 (3.6) 0.79
Severe liver disease 5 (0.7) 17 (1.4) 0.19
Diabetes 257 (35.8) 411 (33.4) 0.28
Diabetes with complications 76 (10.6) 119 (9.7) 0.52
Chronic renal disease 85 (11.9) 174 (14.2) 0.15
Hemi/Paraplegia 10 (1.4) 17 (1.4) 0.98
Any prior malignancy 183 (25.5) 319 (26.0) 0.83
Metastatic solid tumor 29 (4.0) 56 (4.6) 0.59
Illicit drug abuse 9 (1.3) 15 (1.2) 0.95
Nursing home residence 10 (1.4) 7 (0.6) 0.06
Vasopressor use 50 (7.0) 499 (40.6) <0.01
Cardiovascular drug count 90 days prior, mean (SD) 2.0 (1.6) 1.9 (1.6) 0.06
Diabetes drug count 90 days prior, mean (SD) 0.4 (0.8) 0.4 (0.7) 0.04
Inhaled corticosteroids drug count 90 days prior mean (SD) 0.75 (1.0) 0.62 (0.98) 0.01
Pulmonary drug count 90 days prior mean (SD) 2.4 (2.2) 2.0 (2.2) <0.01
Number of primary care clinical visits 1 year prior, mean (SD) 5.0 (3.8) 5.0 (4.4) 0.88
Number of emergency department clinic visits 1 year prior, mean (SD) 1.3 (3.6) 1.4 (2.8) 0.52
Reason for immunosuppression
Taking immunosuppressive drugs 611 (85.2) 961 (78.2) <0.01
Leukemia/lymphoma/multiple myeloma 42 (5.9) 121 (9.9) <0.01
Taking oral corticosteroids 362 (50.5) 649 (52.8) 0.32
AIDS 3 (0.4) 3 (0.2) 0.68
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Demographic, utilization, and comorbidity differences be-
tween NIV and invasive mechanical ventilation groups
were assessed using the Student’s t-test for continuous
variables and the χ2 test and Fisher’s exact test for categor-
ical variables. A multilevel logistic regression analysis was
performed to determine factors associated with the receipt
of NIV (1) versus invasive (0) mechanical ventilation.
Univariate logistic regression analyses were performed
to evaluate the associations between mortality (30-day
or 90-day) and the dichotomized mechanical ventilation
exposure, as well as other prognostic variables. Multi-
level logistic regression analyses were performed with
the dichotomized mechanical ventilation exposure (non-
invasive vs. invasive) as the independent variable. Other
covariates included the model are listed in Table 1. Pa-
tients were considered grouped within VA facilities.
Interaction between smoking status and number of in-
haled corticosteroids was evaluated, as well.
In addition, we performed sub-analyses using only pa-
tients admitted to the ICU and only patients admitted to the
ICU who were also taking vasopressors to account for pos-
sible differences in acute severity of illness between groups.
Vasopressor use for hypovolemia is classified as a major cri-
teria for severe community acquired pneumonia according
to the Infectious Diseases Society of America and the
American Thoracic Society guidelines [3], and so those pa-
tients receiving vasopressor medications during their stay
should be more severely ill. Also, it has been shown that the
increased use of non-invasive ventilation, when used on pa-
tients with acute exacerbations of COPD, has resulted in sig-
nificant reductions in mortality [18]. Therefore, to minimize
the conceivable effect seen in this group of patients, we per-
formed a sub-analysis of patients without COPD. Further,
we performed propensity score matching, based on the
same covariates in the logistic regressions models, to adjust
for known confounders. This resulted in matching 422 pairs
of patients with no statistically significant differences in any
of the variables listed in Table 1. Lastly, we performed multi-
level logistic regression analyses incorporating time (fiscal
year of admission) into the model on the full cohort and
sub-cohorts, as well as conditional logistic regression using
a propensity-matched cohort created with time incorporated
into the model to control for any possible effect of time on
mortality. A Kaplan-Meier curve was generated to assess
90-day survival between groups. The log-rank test was uti-
lized to assess differences in survival.
Statistical significance was found if p < 0.05. All ana-
lyses were performed using STATA 12 (StataCorp, Col-
lege Station, TX).
Results
We identified 1,946 patients who met the inclusion and
exclusion criteria. By cause of immunosuppression, 1,572(81%) had received immunosuppressive medications, 1,011
(52%) received oral corticosteroids, 6 (0.3%) had acquired
immunodeficiency syndrome, and 163 (8%) had a history
of leukemia, lymphoma, and/or multiple myeloma. Of this
cohort, 717 (37%) received NIV and 1,229 (63%) received
invasive mechanical ventilation. Baseline differences be-
tween these two groups are displayed in Table 1.
Predictors of non-invasive mechanical ventilation
There were many variables that were significantly associ-
ated with NIV in the univariate analysis. As displayed in
Table 1, these included smoking cessation status, receipt
of guideline concordant antibiotics, congestive heart fail-
ure, chronic obstructive pulmonary disease, vasopressor
use, elevated diabetic, inhaled corticosteroid and pul-
monary drug counts, and receipt of immunosuppressive
medications.
Table 2 displays predictors of receipt of NIV in the
multilevel regression model. Receipt of guideline con-
cordant antibiotics, congestive heart failure, chronic
obstructive pulmonary disease, and increased inhaled
corticosteroid drug count within 90 days prior to ad-
mission were all significantly associated with receipt of
NIV. ICU admission and vasopressor use were both
significantly associated with a decreased likelihood of
receiving NIV.
30-day mortality
Results of the multilevel logistic regression models are
shown in Tables 3 and 4. NIV was not significantly asso-
ciated with 30-day mortality (OR 0.85, 95% CI 0.66-
1.10). This effect was also not significant in any of our
sub-analyses, as shown in Table 5, nor was it significant
in our models incorporating fiscal year of admission.
However, higher age at admission (OR 1.04, 95% CI
1.03-1.06), any prior hospital admission (OR 1.41, 95%
CI 1.10-1.80), VA priority groups 2 through 6 (OR 1.57,
95% CI 1.17-2.11) and 7 through 8 (OR 2.06, 95% CI
1.34-3.17), any prior malignancy (OR 1.32, 95% CI 1.02-
1.71), metastatic solid tumor (OR 2.49, 95% CI 1.45-
4.30), and vasopressor use (OR 1.75, 95% CI 1.37-2.24)
were significantly associated with increased mortality.
Receipt of guideline concordant antibiotics (OR 0.31,
95% CI 0.24-0.39), black race (OR 0.53, 95% CI 0.30-
0.93) and increasing number of cardiovascular medica-
tions (OR 0.92, 95% CI 0.85-0.99) were associated with
decreased mortality. There was no significant interaction
between smoking status and number of inhaled cor-
ticosteroids. When examining the relationship between
the cause of immunosuppression and 30-day mortality,
leukemia, lymphoma, and/or multiple myeloma (OR 1.96,
95% CI 1.33-2.89) and receipt of oral corticosteroids (OR
1.89, 95% CI 1.48-2.42) were associated with increased
mortality.
Table 2 Results of multivariable regression model for outcome of non-invasive mechanical ventilation
Variables OR 95% CI p-Value
Age at admission 1.02 1.00 1.04 0.12
Men 0.52 0.18 1.45 0.21
Smoke 1.34 0.98 1.83 0.07
Alcohol abuse 0.80 0.44 1.46 0.46
Prior admission 0.79 0.59 1.06 0.12
Guideline concordant antibiotics 1.59 1.14 2.22 0.01
Black 0.71 0.37 1.36 0.30
White 0.86 0.51 1.47 0.59
Hispanic 0.96 0.43 2.11 0.91
Married 1.10 0.85 1.42 0.47
VA priority groups 2–6 0.95 0.69 1.31 0.76
VA priority groups 7–8 1.11 0.68 1.81 0.68
ICU 0.15 0.10 0.20 <0.01
Reason for immunosuppression
Taking immunosuppressive drugs 1.11 0.76 1.61 0.61
Leukemia/lymphoma/multiple myeloma 0.86 0.52 1.41 0.55
Taking oral corticosteroids 1.05 0.79 1.39 0.73
AIDS 4.78 0.49 46.76 0.18
Myocardial infarction 0.64 0.40 1.03 0.06
Congestive heart failure 1.36 1.03 1.80 0.03
Peripheral vascular disease 0.83 0.59 1.18 0.30
Cerebrovascular disease 0.93 0.64 1.34 0.70
Dementia 0.89 0.38 2.09 0.79
Chronic obstructive pulmonary disease 2.01 1.43 2.81 <0.01
Rheumatologic disease 0.53 0.27 1.03 0.06
Peptic ulcer disease 0.88 0.44 1.74 0.71
Severe liver disease 0.60 0.18 1.96 0.39
Diabetes 0.96 0.66 1.38 0.81
Diabetes with complications 0.98 0.61 1.56 0.92
Chronic renal disease 0.97 0.66 1.42 0.87
Hemi/Paraplegia 1.30 0.45 3.78 0.63
Any prior malignancy 1.19 0.88 1.61 0.26
Metastatic solid tumor 1.62 0.87 3.03 0.13
Illicit drug abuse 0.92 0.31 2.75 0.88
Nursing home residence 1.13 0.31 4.17 0.85
Vasopressor use 0.15 0.10 0.21 <0.01
Cardiovascular drug count 90d prior 1.03 0.95 1.13 0.44
Diabetes drug count 90d prior 1.26 0.99 1.60 0.06
Inhaled corticosteroid drug count 90d prior 1.19 1.01 1.41 0.04
Pulmonary drug count 90 days prior 0.98 0.92 1.05 0.56
# of primary care clinical visits 1 year prior 1.00 0.96 1.03 0.80
# of emergency department clinic visits 1 year prior 1.01 0.96 1.06 0.70
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Table 3 Results of multivariable regression model for
outcome of 30-day mortality
Variables OR 95% CI p-Value
Non-invasive mechanical ventilation 0.85 0.66 1.10 0.23
Age at admission 1.04 1.03 1.06 <0.01
Men 0.43 0.17 1.09 0.08
Smoke 0.87 0.66 1.14 0.30
Alcohol abuse 0.60 0.34 1.05 0.08
Prior admission 1.41 1.10 1.80 0.01
Guideline concordant antibiotics 0.31 0.24 0.39 <0.01
Black 0.53 0.30 0.93 0.03
White 0.89 0.57 1.41 0.63
Hispanic 0.70 0.43 1.13 0.14
Married 0.90 0.72 1.12 0.34
VA priority groups 2–6 1.57 1.17 2.11 <0.01
VA priority groups 7–8 2.06 1.34 3.17 <0.01
ICU 1.13 0.84 1.53 0.41
Reason for immunosuppression
Taking immunosuppressive drugs 0.74 0.55 0.99 0.05
Leukemia/lymphoma/multiple myeloma 1.96 1.33 2.89 <0.01
Taking oral corticosteroids 1.89 1.48 2.42 <0.01
AIDS 1.38 0.16 11.59 0.77
Myocardial infarction 0.96 0.65 1.44 0.86
Congestive heart failure 1.00 0.78 1.28 1.00
Peripheral vascular disease 1.23 0.91 1.65 0.18
Cerebrovascular disease 1.03 0.75 1.41 0.87
Dementia 1.12 0.56 2.22 0.75
Chronic obstructive pulmonary disease 0.88 0.67 1.17 0.38
Rheumatologic disease 1.16 0.70 1.91 0.58
Peptic ulcer disease 1.02 0.57 1.81 0.96
Severe liver disease 2.11 0.77 5.78 0.15
Diabetes 0.87 0.63 1.20 0.40
Diabetes with complications 0.92 0.61 1.37 0.67
Chronic renal disease 1.08 0.78 1.50 0.64
Hemi/Paraplegia 0.53 0.21 1.35 0.19
Any prior malignancy 1.32 1.02 1.71 0.03
Metastatic solid tumor 2.49 1.45 4.30 <0.01
Illicit drug abuse 1.53 0.61 3.87 0.37
Nursing home residence 0.55 0.16 1.91 0.35
Vasopressor use 1.75 1.37 2.24 <0.01
Cardiovascular drug count 90d prior 0.92 0.85 0.99 0.04
Diabetes drug count 90d prior 1.03 0.84 1.28 0.76
Inhaled corticosteroid drug count 90d prior 0.99 0.85 1.14 0.85
Pulmonary drug count 90 days prior 0.99 0.93 1.05 0.80
# of primary care clinical visits 1 year prior 1.01 0.99 1.04 0.31
# of ED clinic visits 1 year prior 1.02 0.98 1.05 0.36
Table 4 Results of multivariable regression model for
outcome of 90-day mortality
Variables OR 95% CI p-Value
Non-invasive mechanical ventilation 0.66 0.52 0.84 <0.01
Age at admission 1.06 1.04 1.08 <0.01
Men 0.70 0.28 1.75 0.44
Smoke 0.73 0.56 0.94 0.02
Alcohol abuse 0.71 0.43 1.18 0.18
Prior admission 1.56 1.23 1.98 <0.01
Guideline concordant antibiotics 0.41 0.31 0.53 <0.01
Black 0.37 0.21 0.63 <0.01
White 0.60 0.39 0.93 0.02
Hispanic 0.88 0.54 1.44 0.62
Married 0.89 0.72 1.10 0.29
VA priority groups 2–6 1.40 1.07 1.83 0.02
VA priority groups 7–8 1.47 0.97 2.21 0.07
ICU 1.25 0.95 1.66 0.11
Reason for immunosuppression
Taking immunosuppressive drugs 0.83 0.62 1.13 0.24
Leukemia/lymphoma/multiple myeloma 1.75 1.17 2.60 0.01
Taking oral corticosteroids 1.67 1.32 2.10 <0.01
AIDS 2.63 0.35 20.07 0.35
Myocardial infarction 1.09 0.74 1.59 0.67
Congestive heart failure 1.09 0.86 1.38 0.47
Peripheral vascular disease 1.09 0.82 1.45 0.54
Cerebrovascular disease 1.03 0.76 1.39 0.84
Dementia 1.08 0.55 2.13 0.82
Chronic obstructive pulmonary disease 1.01 0.78 1.33 0.92
Rheumatologic disease 0.65 0.40 1.08 0.10
Peptic ulcer disease 1.18 0.68 2.05 0.56
Severe liver disease 3.87 1.32 11.32 0.01
Diabetes 0.90 0.66 1.22 0.50
Diabetes with complications 0.83 0.57 1.22 0.34
Chronic renal disease 1.16 0.84 1.59 0.36
Hemi/Paraplegia 0.64 0.26 1.57 0.33
Any prior malignancy 1.27 0.98 1.63 0.07
Metastatic solid tumor 3.44 1.85 6.37 <0.01
Illicit drug abuse 1.43 0.56 3.64 0.45
Nursing home residence 0.30 0.09 1.05 0.06
Vasopressor use 2.04 1.59 2.60 <0.01
Cardiovascular drug count 90d prior 0.95 0.88 1.02 0.16
Diabetes drug count 90d prior 1.15 0.94 1.40 0.17
Inhaled corticosteroid drug count 90d prior 1.00 0.87 1.15 0.97
Pulmonary drug count 90 days prior 0.98 0.93 1.04 0.60
# of primary care clinical visits 1 year prior 1.02 0.99 1.05 0.20
# of ED clinic visits 1 year prior 1.01 0.98 1.05 0.55
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Table 5 Effect of non-invasive mechanical ventilation on 30-day mortality and 90-day mortality
Full cohort
multivariable
model (n = 1925)
ICU Sub-cohort
multivariable












OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
30-day mortality 0.85 (0.66, 1.10) 1.05 (0.78, 1.41) 0.68 (0.31, 1.49) 0.97 (0.72, 1.30) 0.87 (0.50-1.54)
90-day mortality 0.66 (0.52, 0.84)* 0.73 (0.55, 0.96)* 0.46 (0.22, 0.97)* 0.74 (0.56, 0.98)* 0.74 (0.44-1.26)
*Indicates p <0.05.
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Figure 1 displays the Kaplan-Meier 90-day survival curves
for the NIV and invasive mechanical ventilation groups.
We found that NIV patients had significantly higher sur-
vival than did invasive ventilation patients (p <0.001).
As shown in Table 4, NIV was associated with de-
creased mortality in the multilevel logistic regression
analysis for 90-day mortality (OR 0.66, 95% CI 0.52-
0.84). This effect remained significant in the ICU, ICU
with vasopressor use, and propensity-matched sub-
group analyses but not in the sub-analysis of patients
without comorbid COPD, as shown in Table 5. Add-
itionally, there were negligible differences when fiscal
year of admission was incorporated into the model.
Smoking cessation (OR 0.73, 95% CI 0.56-0.94), receipt
of guideline concordant antibiotics (OR 0.41, 95% CI
0.31-0.53), black race (OR 0.37, 95% CI 0.21-0.63), and
white race (OR 0.60, 95% CI 0.39-0.93) were also signifi-
cantly associated with decreased risk of 90-day mortality.
Conversely, higher age at admission (OR 1.06, 95% CI
1.04-1.08), prior hospital admission (OR 1.56, 95% CI
1.23-1.98), being in VA priority groups 2 through 6 (OR
1.40, 95% CI 1.07-1.83), severe liver disease (OR 3.87,
95% CI 1.32-11.32), metastatic solid tumor (OR 3.44,
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Figure 1 Kaplan-Meier plot of 90-day survival. Patients
undergoing non-invasive mechanical ventilation had significantly
higher survival than did invasive ventilation patients (p < 0.001 by
the log-rank test).1.59-2.60) were significantly associated with increased
90-day mortality. There was no significant interaction
between smoking status and number of inhaled corti-
costeroids. In examining the association between cause
of immunosuppression and 90-day mortality, we found
leukemia, lymphoma, and/or multiple myeloma (OR
1.75, 95% CI 1.17-2.60) and receipt of oral corticoste-
roids within 90 days prior to index admission (OR
1.67, 95% CI 1.32-2.10) to be associated with increased
mortality.
Discussion
We found the use of NIV in elderly hospitalized im-
munocompromised pneumonia patients to be associated
with decreased mortality at 90-days, but not at 30-days,
after adjusting for potential confounders. Additionally,
we observed that the receipt of guideline-concordant an-
tibiotics to be associated with decreased odds of mortal-
ity, at both 30- and 90-days. These data suggest that
physicians should consider the use of NIV, when appro-
priate, for elderly immunocompromised patients hospi-
talized with pneumonia. At minimum, patients receiving
NIV fared no worse than similar patients receiving inva-
sive ventilation.
Though previous studies have evaluated NIV in im-
munocompromised patients, many have not specifically
examined mortality rates of NIV versus invasive mechan-
ical ventilation for immunocompromised pneumonia pa-
tients. Similar studies have investigated and found a
beneficial association between NIV use and survival in pa-
tients with hematological malignancies [19,20]. Our study
too found similar beneficial effects of NIV on mortality,
even while specifically restricting to pneumonia patients
and including other forms of immunosuppression. An-
other prior study of patients with severe acute hypoxemic
respiratory failure found that patients receiving NIV had a
significantly decreased risk of 90-day mortality when com-
pared to patients receiving high-concentration oxygen.
However, this study did not strictly evaluate immunocom-
promised patients, and it did not compare 90-day mortal-
ity between patients receiving NIV with those receiving
invasive ventilation [21]. A study by Hilbert et al. [9] eval-
uated NIV for immunocompromised patients with pul-
monary infiltrates, fever, and early stages of hypoxemic
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in in-hospital mortality for patients receiving NIV, but the
patients in this study were assessed prior to the need for
intubation, and so had not reached a critical state. Further,
the use of NIV was only compared to the use of standard
treatment with supplemental oxygen and no ventilatory
support. Lastly, a study by Razlaf and colleagues [22] in-
vestigated NIV failure in immunocompromised patients.
This study also demonstrated that NIV in immunocom-
promised patients resulted in weaning to spontaneous
breathing and eventual hospital discharge in almost half of
study subjects. Though mortality was evaluated, this study
proved that severity of illness at ICU admission was a sig-
nificant predictor for NIV failure, which may explain why
some patients who are more critically ill receive invasive
ventilation instead of NIV.
Our study specifically examines all-cause mortality
and its association with the use of NIV and invasive
mechanical ventilation for elderly immunocompromised
patients with pneumonia. We found a positive associ-
ation between the use of NIV and mortality, particularly
when we investigated all-cause 90-day mortality. To our
knowledge, this has not been shown in previous studies.
In our univariate analyses, the use of NIV was associated
with lower 30-day and 90-day mortality. After adjusting
for demographic, utilization, and comorbid factors, as
well as underlying cause of immunosuppression, NIV
was only associated with lower mortality after 90 days. It
has previously been shown that pneumonia plays a pri-
mary role in death within 30 days of hospitalization for
patients diagnosed with community-acquired pneumo-
nia. Likewise, comorbid conditions are more likely to
play a prominent role in death within 90 days [23]. The
same may be true for immunocompromised patients
with pneumonia. Accordingly, the same comorbidities
that contribute to the need for invasive mechanical ven-
tilation may also be contributing to the higher mortality
after 30-days we found for patients receiving invasive
mechanical ventilation. However, we repeated our ana-
lyses only in patients admitted to the ICU and only in
patients admitted to the ICU who were also taking vaso-
pressors, in an attempt to equalize possible differences
in severity of illness between the groups. Likewise, we
repeated our analyses on patients without comorbid
COPD. Even still, those patients receiving NIV did no
worse than those receiving invasive mechanical ventila-
tion. We also used propensity score matching to create a
cohort of patients with balanced baseline covariates be-
tween groups. The effect of NIV remained significant for
90-day mortality and insignificant for 30-day mortality
in all of these sub-cohort analyses, as shown in Table 5.
Our survival analysis indicated a significantly higher 90-
day survival probability for those who received NIV
compared to those who did not. The Kaplan-Meiercurve shows that the risk of mortality is comparable be-
tween the two groups for about the first 10 days, after
which the invasive mechanical ventilation group appears
to have a sharper drop in survival. This may suggest in-
vasive mechanical ventilation could lead to complica-
tions contributing to elevated mortality over a longer
period of time.
Aside from the use of NIV, we also identified other in-
teresting variables significantly associated with 30-day
and 90-day mortality. One significant finding in our
study related to the use of antibiotics concordant with
the American Thoracic Society / Infectious Diseases So-
ciety of America community-acquired pneumonia guide-
lines. Though the guidelines put forth by these societies
do not address immunocompromised patients, we found
these recommendations to be highly beneficial for im-
munocompromised patients for both 30-day and 90-day
mortality.
Further, we examined the underlying cause of im-
munosuppression and its relationship to our outcomes.
We found receipt of immunosuppressive medications to
be associated with decreased 30-day and 90-day mortal-
ity. This association may be explained by the concept
that patients receiving immunosuppressive medications
are under closer watch by their physicians. As such,
these patients may receive more timely care than others.
Our study has limitations. First, we did not have clin-
ical information such as physical exam, laboratory, or
radiographic data. Consequently, we could not account
for patients who may have responded more favorably to
NIV, such as patients with hypercapnic respiratory fail-
ure. Second, we did not include specific measures of se-
verity in our analysis, such as the Pneumonia Severity
Index or CURB-65, as we were missing several necessary
variables. However, we did adjust for several demo-
graphic elements and comorbid conditions, which are
included in these measures. Likewise, we performed sub-
group analyses using only ICU patients and only ICU
patients receiving vasopressors in an effort to make non-
invasive and invasive mechanical ventilation patients
comparable in level of severity and reduce selection bias.
Further, we could not account for contraindications for
use of NIV, such as upper gastrointestinal obstruction,
gastrointestinal bleeding, or recent upper gastrointes-
tinal, facial, or upper airway obstruction. As such, pa-
tients with these conditions would not be candidates
for NIV, due to the mere fact that they had these con-
ditions. Additionally, it is possible that patients diag-
nosed with obstructive sleep apnea and treated with
continuous positive airway pressure may have skewed
the results. Lastly, data regarding NIV failure was un-
available to us. It has previously been shown that pa-
tients failing NIV have an overall increased mortality,
even greater than patients receiving elective invasive
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sive and non-invasive ventilation during their index
hospitalization were removed from our analyses, thus
eliminating this possible bias.
Conclusions
Our study reveals significant differences in mortality be-
tween those elderly immunocompromised patients with
pneumonia who received NIV versus those who received
invasive mechanical ventilation. Specifically, we found a
beneficial association between the use of NIV and mor-
tality. Additionally, the use of guideline-concordant anti-
biotics in the immunocompromised with pneumonia
was significantly associated with lower 30-day and 90-
day mortality. Though our study is observational in na-
ture, overall our results suggest the use of NIV in this
elderly patient population is associated with decreased
mortality as compared to invasive mechanical ventila-
tion. Therefore, physicians should consider the use of
NIV, when appropriate, for immunocompromised pa-
tients hospitalized with pneumonia. However, additional
studies, especially randomized controlled trials, are
needed to confirm our findings.
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